



Post Authorisation Assessments

Daxocox 45 mg Tablets for Dogs

Vm 32742/5003

04 March 2026	One-off alignment of the product information with version 3.0 of the QRD templates. Addition of a new indication: For the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery.
07 October 2025	Approval of mock-ups.
19 September 2025	Extension of the finished product shelf-life from 4 years to 5 years.
26 March 2025	Change in pack size of the finished product. Change in pack size of finished product.
04 February 2025	Approval of mock ups.
17 December 2024	Change in the re-test period/storage period of the active substance.
09 January 2025	Removal of the dosing table from Section 4.9 of the SPC and Section 8 of the package leaflet.
15 May 2024	Change in the address of a manufacturer of the active substance. Change in the name of a quality control testing site.
17 April 2024	Change in the holding time of a bulk product.
27 March 2024	Extension of the shelf life of the finished product - As packaged for sale (supported by real time data).
03 March 2023	Change in the name and address of a manufacturer of a starting material, used in the manufacture of the active substance.
23 February 2023	Change of GB Local Representative address. From Animalcare Ltd, 10 Great North Way, York, YO26 6RB to Animalcare Ltd, Moorside, Monks Cross, York, YO32 9LB.
10 June 2022	Adjustments to the size of the blister and outer carton mock ups for manufacturing needs.